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A B S T R A C T
Objective: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening
pneumonia that often occurs in the setting of increased inflammation or “cytokine storm”. Anti-cytokine
treatments are being evaluated but optimal patient selection remains unclear, and the aim of our study is to
address this point.
Methods: Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19 pneu-
monia were evaluated in a single centre retrospective study. Patients were divided in two groups: 42 severe cases
(TOCI) with adverse prognostic features including raised CRP and IL-6 levels, who underwent anti-cytokine
treatments, mostly tocilizumab, and 69 standard of care patients (SOC).
Results: In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62%
of cases were ventilated and there were three deaths (17.8 ± 10.6 days, mean follow up) with 7/26 cases
remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection. One fatality
occurred in the 15 TOCI cases treated on noninvasive ventilation and one serious bacterial superinfection. Of the
69 cases in SOC, there was no fatalities and no bacterial complications. The TOCI group had higher baseline CRP
and IL-6 elevations (p < 0.0001 for both) and higher neutrophils and lower lymphocyte levels (p = 0.04 and p
= 0.001, respectively) with the TOCI ventilated patients having higher markers than non-ventilated TOCI pa-
tients.
Conclusion: Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI
cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy time in anti-
cytokine randomized trials will be key.
1. Introduction
The outbreak of novel coronavirus 2019 (COVID-19) caused by se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global
pandemic [1]. About twenty-five percent of patients have a seriously ill
disease. A fraction of them may develop a very severe pneumonia
which may progress to acute respiratory distress syndrome (ARDS) or
end-organ failure that may be associated with a cytokine storm syn-
drome [2]. Laboratory features associated with ARDS or death included
neutrophilia, coagulation dysfunction [e.g., higher lactate dehy-
drogenase (LDH) and D-dimer] [3]. Markedly high levels of interleukin
(IL)-2R, IL-6, IL-10, and TNF-α and the absolute numbers of CD4+ and
CD8+ T lymphocytes being markedly low seem to characterize the
most severe cases [4]. Starting from the first preliminary experience on
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the apparent efficacy of tocilizumab in COVID-19 pneumonia [5], many
multicenter trials are ongoing to test anti-cytokine treatments in criti-
cally ill patients.
Nevertheless, robust data to predict the outcome of COVID-19
pneumonia after the hospital admission are still lacking [6], though
they are urgently needed in order to facilitate the assessment of anti-
cytokine treatment efficacy in worse prognosis patient groups and not
milder disease. The aim of this retrospective study was to evaluate
baseline laboratory and immunological features in patients hospitalized
for COVID-19 pneumonia and to explore such parameters in relation-
ship to standard of care (SOC group) therapy versus anti-cytokine
therapy, mainly tocilizumab, (TOCI group) that was mostly used either
in ventilated patients in the ICU or non-invasively ventilated patients,
mostly in the ward setting. Our single centre experience and approach
showed that the milder hospitalized SOC group faired well as did cases
with cytokine storm treated with tocilizumab outside of the ICU setting
without ventilator support. Severe complications including bacterial
infections complicated tocilizumab in the ICU setting but not ward-
based tocilizumab therapy. Therefore, randomized trials should target
non-ICU patients to prevent cytokine storm evolution.
2. Methods
This study was undertaken to identify laboratory features for more
serious COVID-19 disease (i.e., to determine which cases that might
theoretically benefit from anti-cytokine drugs). In this monocentric
retrospective case-control study, the clinical and immunological char-
acteristics of 111 consecutive patients with COVID-19 were analyzed.
Patients were admitted to our hospital from February 29 to April 6,
2020. All but six patients presented to our hospital with six cases
transferred from three other hospitals (all of whom eventually received
tocilizumab).
Oral or written consent was obtained from patients. The study was
conducted in accordance with the ethical principles of the Helsinki
Declaration and ethical approval was given by local Ethics Committee
(CEUR-2020-Os-102).
Besides clinical evaluation, the level of CRP and IL-6, when avail-
able, guided the decision towards anti-cytokine treatments. Clinical
decisions for the treatment of all these patients were taken usually
within the first week after the admission, and during this time, the la-
boratory tests were repeated. Demographic, clinical and laboratory
characteristics, treatments and outcome data were collected.
Identification of cases of COVID-19 virus was based on the detection of
unique sequences of virus RNA by nucleic acid amplification tests
(NAAT) such as RT-PCR with confirmation by nucleic acid sequencing.
The following genes were investigated: E gene for screening and then
RdRp and N genes of SARS-CoV-2 for confirmation [7].
Some laboratory data analysed at the admission are reported in
Table 1, including flow cytometry analysis with antibodies for the fol-
lowing subpopulations: CD19+ B cells, CD3+ CD4+ T cells, CD3+
CD8+ T cells, CD56+ NK cells, platelet count (cell/μL) and serum IL-6
(pg/mL), measured by CE_IVD electrochemiluminescence immunoassay
(Elecsys IL6, Cobas, physiological range < 7 pg/mL) with results being
available within 48 h.
Variables were reported as mean and standard deviation or median
and interquartile range (IQR), as appropriate, or frequency rates and
percentages if categorical; consequently, comparisons between TOCI
and SOC groups were made by parametric tests (t-test for two in-
dependent samples) or no parametric tests (Mann–Whitney test) for
continuous variables. Proportions were compared by χ2 test, or Fisher
exact test. Bivariate correlation was made by two tailed Pearson or
Spearman tests. All statistical analyses were performed using SPSS
version 15.0 software (SPSS Inc.). For unadjusted comparisons, a 2-
sided α of less than 0.05 was considered statistically significant. No
corrections were made for multiple comparisons due to the explorative
nature of the study.
When the laboratory parameters were available, the patients were
classified into two groups: the first group comprised 42 cases who de-
veloped a serious COVID-19 disease that were deemed suitable for to-
cilizumab 8 mg/kg intravenously as a single infusion. In TOCI failures,
two patients were then treated with anakinra 200 mg/day sub-
cutaneously for three consecutive days. A second group of 69 cases who
received supportive therapy [standard of care group (SOC)] comprised
those initially admitted to the hospital for COVID-19, and who were
treated with SOC based on clinical and laboratory features (Table 1).
3. Results
3.1. Patients’ characteristics and outcome
Table 1 reports the main demographic and clinical features of the
two groups. Patients were predominantly male (77/111, 69.4%) with a
mean age of 58.5 ± 13.6 years. Patients in TOCI were slightly older
than SOC (p = 0.02) (Table 1). Globally, at the hospital admission,
resting oxygen saturation equal or below 93% was available for 45
patients (40.5%).
Antiviral treatments were employed in 100% of TOCI group and
80% of SOC group (Table 1). Notably, nearly 40% of TOCI group re-
ceived glucocorticoids but none of the SOC group did (Table 1). There
was no difference between groups regarding the time of reaching a
negative swab test (supplemental file).
Among TOCI group, 18 (43%) patients were originally referred to
the Infectious Disease Unit with three being subsequently transferred to
ICU before tocilizumab administration (Fig. 1) with 24/42 patients
(57%) ICU transfers within 24 h of hospital admission. The majority of
patients received tocilizumab in the ICU (27/42, 64.3%) with the re-
maining 15 cases receiving TOCI on the ward. Tocilizumab was ad-
ministered after a mean time of 8.4 ± 3.7 days from disease onset as
add-on treatment. Of the 27 patients that were transferred to ICU, 26
(96.3%) were intubated with subsequent tracheostomies in 8 (7.2%),
while only one was on noninvasive ventilation.
There were no fatalities in the SOC group (Fig. 1). Overall, at April
18, 2020, 4/42 TOCI patients had died (9.5%). Of the TOCI ventilated
patients 15/26 (57.7%) had a good outcome. When combined with
fatality rate, 11/26 (42.3%) patients in the TOCI ventilated group can
be deemed as non-responders. By contrast, 15/16 (93.7%) TOCI non-
ventilated patients can be deemed as responders with a single fatality
(Fig. 1). Importantly, at the hospital admission, TOCI patients who
required invasive ventilation showed higher levels of inflammation
markers, higher LDH and, notably, lower lymphocyte count than non-
ventilated TOCI patients (Table 2).
Eighteen out 111 patients (16.2%) experienced bacterial super-
infection that were almost exclusively in the TOCI group (Fig. 1). Three
out of four deaths and 17/18 bacterial complications occurred in ICU
(all three deaths as well as all the bacterial complications occurred in
patients on ventilators or in the non-ventilated TOCI group (Fig. 1).
While all the patients in the SOC group recovered, in the TOCI
group, 9/42 (21.4%) patients completely recovered, and 21/42 (50%)
patients showed a clear and rapid improvement after tocilizumab. A
rapid improvement on anakinra after tocilizumab occurred in one case.
In the 21 recovered TOCI treated group complicating infections arose in
11 (52.4%). In the remaining 12 non-responder patients, four of them
died, including one treated with anakinra after tocilizumab failure, and
almost all showed co-morbidities including hypertension, obesity, is-
chemic heart disease or diabetes, or experienced superinfections, which
substantially complicated the course. At the last available follow-up on
May 13th, i.e. after two months from the first TOCI patient and more
than one month from the last TOCI patient, 7/42 TOCI patients had
died (16.7%) (another 3 patients from the TOCI-ventilated group), 30/
42 (71.4%) were discharged home, whilst 5/42 (11.9%) remained
hospitalised, only one of whom in ICU.
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3.2. Retrospective laboratory marker comparison between treatment groups
At hospital admission, TOCI group showed a significantly higher
level of systemic inflammation as resulted by the significant difference
of CRP levels [mg/L, median (IQR)] [79.05 (47.8–186.22) vs 24.1
(7.3–72.6) p < 0.0001)], and IL-6 levels [pg/mL, median (IQR)] [63.5
(37.25–135.5) vs 18.5 (10.25−33), p < 0.0001]. Also, some other
laboratory features mirrored a higher level of systemic disease and
organ damage in TOCI group, such as LDH [IU/L, median (IQR)] [625
(482−829) vs 442 (375−577), p = 0.001] and CK [IU/L, median
(IQR)] [134 (84.5−365.5) vs 93 (57−146), p = 0.007].
The TOCI group showed a significantly higher neutrophil count
(cells/μL) [4565 (3062.5−6190) vs 3670 (2285−4905), p = 0.04],
lower lymphocyte count [cell/μL, median (IQR)] [685 (545−1022.5)
vs 940 (760−1195), p = 0.001], CD4+ T cell [244.5
(158.75−406.25) vs 370 (269.5−497), p = 0.02], CD8+ T cell sub-
population [77 (48−195.75) vs 180 (111−366), p = 0.004]. Also,
neutrophil to lymphocyte ratio (NLR) was significantly higher in TOCI
group than in SOC group [5.6 (3.5−11.8) vs 3.6 (2.2−5.4), p =
0.001]. The TOCI group also showed basal higher levels of LDH (p =
0.001) and CK (p = 0.007), possibly indicating cardiac injury that is a
known bad prognostic sign.
Table 3A reports the correlations between CRP levels and the levels
of the other biomarkers in the whole population (TOCI + SOC) and
table 3B resports the same results after excluding those patients with
Fig. 1. The chart illustrates the outcomes of the two treatment groups.
Legend: TOCI, tocilizumab treatment group; SOF, standard of care group; MOF, multi-organ failure; ICU, intensive care unit; NIV, non-invasive ventilation; PE,
pulmonary embolism.
Table 2
Laboratory marker comparison between the two Tocilizumab treated sub-
groups.
TOCI on NIV/O2 (N
= 16)
TOCI on ventilators (N =
26)
p value
CRP, mg/L 59.3 (21.6−112.7) 114.6 (5.25−210) 0.04
IL-6, pg/mL 58 (28.45−78.5) 78.8 (46−161) 0.06
WBC, cell/μL 4425 (3210−6115) 6180 (5230−8130) 0.009
Neutrophil, cell/μL 3130 (2310−4885) 7235 (5430−9072) 0.01
Lymphocyte, cell/
μL
1020 (635−1165) 650 (445−775) 0.01
NLR 3.5 (2.5−5.1) 8.2 (4.7−15.7) 0.001
LDH, IU/L 494 (246.5−599) 744 (580.75−1057) 0.001
CK, IU/L 101 (78−179) 197 (104.5−382.75) 0.13
Legend: TOCI, tocilizumab treatment group; NIV, non-invasive ventilation; CRP,
C-reactive protein; IL, interleukin; LDH, lactate dehydrogenase; CK, creatine
kinase; WBC, white, blood cell count; NLR, neutrophil to lymphocyte ratio. Data
are presented as median (IQR).
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the worst clinical presentation at the admission (N = 24). A moderate
to high correlation (>0.5) was found between CRP and the following
variables: D-dimer, LDH, neutrophil count and NLR (Table 3 A) .
By excluding those patients admitted to the ICU within 24 h (i.e.,
the most serious) (Table 3B),correlations between CRP and IL-6, total
white blood cell count, neutrophil count, NLR, LDH were still sig-
nificant (Table 3B).
Furthermore, the same analysis in the whole cohort by splitting the
two group (N = 42 for TOCI and N = 69 for SOC), showed that
baseline CRP value correlated with IL-6, D-dimer, LDH, WBC, neu-
trophil count and NLR only in the SOC group, while in the TOCI group,
baseline CRP correlated only with LDH, WBC, neutrophil and NLR (data
not shown).
4. Discussion
Our retrospective study was designed to evaluate which baseline
standardized laboratory features in hospitalized COVID-19 pneumonia
may facilitate optimal employment of experimental anti-cytokine
therapy [8,9]. Some case reports and one case series on the treatment
with tocilizumab have been reported in the literature, suggesting some
benefits in seriously ill patients [10–16]. More clearly, our data sug-
gested that tocilizumab treatment in patients with cytokine storm fea-
tures may be more effective outside of the ICU setting in non-ventilated
patients. However, there were differences in the degree of inflammation
between non-ventilated and ventilated patients treated with tocili-
zumab, so it cannot be inferred that use of tocilizumab prior to ICU
admission is superior, given the generally milder inflammation in the
former group. Also, serious superimposed bacterial infections were
largely confined to the ICU. However, looking at long-term follow-up
(i.e. at least 30 days after tocilizumab), around 70% of TOCI patients
recovered with a fatality rate of 17%.
Our findings confirmed that the milder patient group receiving
standard of care therapy without the utilization of tocilizumab all made
full recoveries. Our findings do point towards trials focused on the
earlier use of such therapeutic strategies. Notably, our SOC and TOCI
groups were different in terms of co-treatments, which could have af-
fected the overall outcome, and all of the TOCI cases also received
antiviral therapy. These findings are preliminary and the results of
ongoing randomized controlled trials will definitely clarify anti-cyto-
kine use.
In our study, neutrophilia, lymphopenia, in particular low CD8 + T
cell count rather than CD4+ T cell, higher CRP, higher LDH and higher
CK showed the highest significance to distinguish the two patient
groups at initial hospital admission. Also, serum IL-6 was significantly
higher in the TOCI group, thus reflecting the very high inflammatory
state of those patients at baseline. Very recently, IL-6 serum levels were
also closely correlated with viral load in critically ill patients and it is
important to point out that all our patients belonging to TOCI group
received anti-viral agents [17]. Notably, baseline CRP and IL-6 con-
tinued to distinguish the two groups (TOCI versus SOC) even after ex-
cluding the most seriously ill patients from analyses. Thus, these bio-
markers could useful for decision making. Notably, a higher NLR, as
well as a higher monocyte to lymphocyte ratio, have been associated
with mortality and imaging progression in hospitalized patients for
COVID-19 [18–20]. It is well known that NLR is a biomarker for poor
outcome even in various cancers [21]. An interesting feature of our
TOCI treated cases was that the lymphocyte counts were substantially
higher on ward treated subjects suggesting that the COVID-19 pneu-
monia was not being treated at an earlier time point but that an in-
trinsically milder group of COVID-19 was being targeted in that setting.
Lymphocyte biology probably plays a great role in the pathogenesis
of COVID-19 disease [4,22–25].
Since CD4+ T cells and CD8+ T cells are a crucial arm against
infections [26], our findings also indicated that the lymphopenia in the
TOCI group may be relevant for secondary infections. Given that,
treatment with tocilizumab might favor the persistence of the virus and
iatrogenic infections. Anakinra might be safer and more flexible than
repeating tocilizumab infusion in seriously ill patients.
A role for anticoagulation is increasingly recognized in severe
COVID-19 [27,28]. In our study, a significant correlation between CRP
and D-dimer, as well as with LDH and neutrophil count (and NLR) was
shown. Very recent data showed that low molecular weight heparin or
unfractionated heparin at prophylactic doses are associated with a re-
duced short-term mortality in more severe COVID-19 patients [28], and
most of our patients, particularly, in ICU, were administered heparin
which may have impacted on the overall outcome. Moreover, in-
flammatory diseases carry a higher risk of thrombosis, as seen in
chronic autoimmune diseases [29]. It remains to be seen whether the
possible efficacy of anti-cytokine therapy may be even to mitigate
against immunothrombosis. Increased levels of LDH and CK may also
reflect the level of the organ damage in a systemic disease, as occurs in
the macrophage activation syndrome [30], where a hypercoagulable
state often complicates the course, and it may be the case for COVID-19.
Thus, it is not surprisingly that LDH has been already noticed as bio-
marker of severity as long as neutrophils, in COVID-19 [3,31].
This study has several limitations. It is a retrospective study, with
some missing data due to the emergency context in which it has been
realized. No conclusions on the efficacy and safety of treatment ap-
proach employed can be provided. Six patients were transferred from
other hospitals so original baseline values from the first admission were
unavailable. About 50% of the TOCI group were admitted to the ICU
within 24 h from admission, thus they already presented a more serious
disease at the time of admission. The follow-up started from admission
to our hospital, however, only 6 patients were transferred from other
hospitals. Finally, measurement of viral load was not available, while
viral clearance was finally assessed by repeating swab test in almost all
the patients (see supplemental material). Nevertheless, the cohort is
monocentric and it showed similar characteristics to those reported by
Wang et al. [2], thus supporting the results, though preliminary.
To conclude, our study showed that TOCI treated patients COVID-19
pneumonia were at the highest risk of cytokine storm [32]. However,
Table 3
(A) Bivariate correlations between CRP levels and other biomarkers. (B)
Bivariate correlations between CRP levels and other biomarkers by excluding
those patients transferred to ICU within 24 h from the admission (N = 24).
Variable Spearman’s rho
correlation coefficient
p value Number of
observations, N (%)
IL-6 0.46 <0.0001 90 (81.1)
D-dimer 0.63 <0.0001 39 (35.1)
LDH 0.62 <0.0001 102 (91.9)
CK 0.23 0.03 94 (84.7)
Total WBC count 0.49 <0.0001 108 (97.3)
Neutrophil count 0.60 <0.0001 103 (92.8)
Lymphocyte
count
−0.26 0.002 103 (92.8)




p value Number of
observations, N (%)
IL-6 0.42 0.0002 71 (63.4)
D-dimer 0.62 0.0002 31 (27.9)
LDH 0.48 <0.0001 82 (73.9)
CK 0.12 0.29 78 (70.3)
Total WBC count 0.43 <0.0001 87 (78.4)
Neutrophil count 0.50 <0.0001 83 (74.8)
Lymphocyte
count
−0.1 0.38 83 (74.8)
NLR 0.44 <0.0001 83 (74.8)
Legend: IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC,
white blood cell count; NLR, neutrophil to lymphocyte ratio.
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long-term data are reassuring, overall fatality rate being around 17% in
TOCI group. Tocilizumab use prior to ventilation in ICU may be optimal
since 50% of such cases died, remain ventilated and show serious su-
perinfection. Whether the use of tocilizumab prior to ventilation will be
vindicated in randomized trials is of major interest. Our findings also
showed that cases receiving tocilizumab on ventilation generally had
higher levels of inflammation and lower lymphocyte count than non-
ventilated TOCI treated subjects, possibly suggesting that the latter
group has an intrinsically milder disease with a better prognosis.
Timing of anti-cytokine therapy appears to be a key issue.
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